Literature DB >> 12118340

In vitro pharmacological characterizations of the anti-angiogenic and anti-tumor cell migration properties mediated by microtubule-affecting drugs, with special emphasis on the organization of the actin cytoskeleton.

Caroline Hayot1, Sophie Farinelle, Robert De Decker, Christine Decaestecker, Francis Darro, Robert Kiss, Marc Van Damme.   

Abstract

The aim of the present work is to investigate whether microtubule-affecting drugs including vincristine, vinblastine, vindesine and vinorelbine are able to produce an anti-angiogenic effect at non-cytotoxic doses in the same way of taxol. The cytotoxic effects were determined by means of the colorimetric MTT assay, and the anti-angiogenic effects on HUVEC cells growing on Matrigel and forming capillary networks. Sixteen additional drugs (camptothecin, SN38, topothecan, adriamycin, daunomycin, etoposide, bleomycin, melphalan, mitomycin C, TNP-470, cisplatin, carboplatin, 5-fluorouracil, methotrexate, suramin and batimastat) were used as control in order to test the specificity of the microtubule-affecting drug effects. We also investigated by means of videomicroscopy whether microtubule-affecting drugs could produce anti-migratory effects at non-cytotoxic doses on tumor cells. Finally, we used computer-assisted fluorescence microscopy to characterize the influence of microtubule-affecting drugs on the polymerization/depolymerization dynamics of the actin cytoskeleton in tumor cells. Our results show that taxol, vincristine and vindesine behave similarly in their ability to reduce the capillary network formation by HUVEC cells cultured on Matrigel. These anti-angiogenic effects appear at non-cytotoxic concentrations. In contrast, vinblastine and vinorelbine produce apparent anti-angiogenic effects by direct cytotoxicity. Microtubule-affecting agents are also able to significantly reduce the level of migration of tumor cells at non-cytotoxic concentrations, some of these effects may occur via modifications to the actin cytoskeleton organization. Several types of microtubule-affecting agents could be used as anti-angiogenic agents by administering them at non-cytotoxic concentrations, and some microtubule-affecting agents abandoned in pharmacological assays could turn out to be potent anti-migratory drugs acting on tumor cells, though without being too cytotoxic.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12118340

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  15 in total

1.  A novel microtubule-modulating agent EM011 inhibits angiogenesis by repressing the HIF-1α axis and disrupting cell polarity and migration.

Authors:  Prasanthi Karna; Padmashree C G Rida; Ravi Chakra Turaga; Jinmin Gao; Meenakshi Gupta; Andreas Fritz; Erica Werner; Clayton Yates; Jun Zhou; Ritu Aneja
Journal:  Carcinogenesis       Date:  2012-06-07       Impact factor: 4.944

2.  Amphiphilic suramin dissolves Matrigel, causing an 'inhibition' artefact within in vitro angiogenesis assays.

Authors:  Natalie L Prigozhina; Andrew J Heisel; Jordan R Seldeen; Nicholas D P Cosford; Jeffrey H Price
Journal:  Int J Exp Pathol       Date:  2013-09-02       Impact factor: 1.925

Review 3.  Interphase microtubules: chief casualties in the war on cancer?

Authors:  Angela Ogden; Padmashree C G Rida; Michelle D Reid; Ritu Aneja
Journal:  Drug Discov Today       Date:  2013-11-04       Impact factor: 7.851

4.  Inhibition of human vascular endothelial cell migration and capillary-like tube formation by the microtubule-stabilizing agent peloruside A.

Authors:  Ariane Chan; A Jonathan Singh; Peter T Northcote; John H Miller
Journal:  Invest New Drugs       Date:  2015-03-31       Impact factor: 3.850

5.  3D-QSAR studies of latrunculin-based actin polymerization inhibitors using CoMFA and CoMSIA approaches.

Authors:  Mohammad A Khanfar; Diaa T A Youssef; Khalid A El Sayed
Journal:  Eur J Med Chem       Date:  2010-05-12       Impact factor: 6.514

6.  Inhibition of SIRT2 potentiates the anti-motility activity of taxanes: implications for antineoplastic combination therapies.

Authors:  Katiuscia Bonezzi; Dorina Belotti; Brian J North; Carmen Ghilardi; Patrizia Borsotti; Andrea Resovi; Paolo Ubezio; Antonella Riva; Raffaella Giavazzi; Eric Verdin; Giulia Taraboletti
Journal:  Neoplasia       Date:  2012-09       Impact factor: 5.715

7.  Anti-angiogenic effects of SN38 (active metabolite of irinotecan): inhibition of hypoxia-inducible factor 1 alpha (HIF-1alpha)/vascular endothelial growth factor (VEGF) expression of glioma and growth of endothelial cells.

Authors:  Hiroshi Kamiyama; Shingo Takano; Koji Tsuboi; Akira Matsumura
Journal:  J Cancer Res Clin Oncol       Date:  2004-12-04       Impact factor: 4.553

8.  Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agents.

Authors:  Nikolai M Evdokimov; Severine Van Slambrouck; Petra Heffeter; Lee Tu; Benjamin Le Calvé; Delphine Lamoral-Theys; Carla J Hooten; Pavel Y Uglinskii; Snezna Rogelj; Robert Kiss; Wim F A Steelant; Walter Berger; Jeremy J Yang; Cristian G Bologa; Alexander Kornienko; Igor V Magedov
Journal:  J Med Chem       Date:  2011-03-09       Impact factor: 7.446

9.  Antiangiogenic effect of docetaxel and everolimus as individual and dual-drug-loaded micellar nanocarriers.

Authors:  Gyan P Mishra; Bhuvana Shyam Doddapaneni; Duc Nguyen; Adam W G Alani
Journal:  Pharm Res       Date:  2013-09-25       Impact factor: 4.200

10.  Semisynthetic latrunculin derivatives as inhibitors of metastatic breast cancer: biological evaluations, preliminary structure-activity relationship and molecular modeling studies.

Authors:  Mohammad A Khanfar; Diaa T A Youssef; Khalid A El Sayed
Journal:  ChemMedChem       Date:  2010-02-01       Impact factor: 3.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.